MCID: GST027
MIFTS: 54

Gastric Lymphoma

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Gastric Lymphoma

MalaCards integrated aliases for Gastric Lymphoma:

Name: Gastric Lymphoma 12 77 54 30 56 15 74
Familial Primary Gastric Lymphoma 54 45 74
Primary Gastric Lymphoma 54
Lymphoma of the Stomach 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10540
MeSH 45 C535648
NCIt 51 C4636

Summaries for Gastric Lymphoma

MalaCards based summary : Gastric Lymphoma, also known as familial primary gastric lymphoma, is related to lymphoma, mucosa-associated lymphoid type and lymphoma. An important gene associated with Gastric Lymphoma is BCL6 (BCL6 Transcription Repressor), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Regulation of TP53 Activity. The drugs Amoxicillin and Metronidazole have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and liver, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 77 Primary gastric lymphoma (lymphoma that originates in the stomach itself) is an uncommon condition,... more...

Related Diseases for Gastric Lymphoma

Diseases related to Gastric Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 160)
# Related Disease Score Top Affiliating Genes
1 lymphoma, mucosa-associated lymphoid type 32.1 ATP12A BCL10 BCL2 BCL6
2 lymphoma 30.7 BAX BCL10 BCL2 BCL6
3 follicular lymphoma 29.9 BCL10 BCL2 BCL6
4 diffuse large b-cell lymphoma 29.6 BCL10 BCL6 TP53
5 burkitt lymphoma 29.5 BAX BCL2 BCL6
6 acquired immunodeficiency syndrome 29.5 ALB BCL6 TP53
7 mantle cell lymphoma 29.4 BCL2 BCL6 TP53
8 marginal zone b-cell lymphoma 29.3 BCL10 BCL2 BCL6
9 gastric adenocarcinoma 29.2 BAX BCL2 TP53 VEGFA
10 lymphoma, non-hodgkin, familial 29.2 BAX BCL10 BCL2 BCL6 TP53
11 b-cell lymphomas 28.8 BAX BCL10 BCL2 BCL6 TP53
12 lymphoma, gastric non hodgkins type 11.1
13 nodal marginal zone lymphoma 10.3
14 central nervous system lymphoma 10.3 BCL6 TP53
15 mature teratoma 10.3 PCNA TP53
16 oral leukoplakia 10.3 PCNA TP53
17 fibrillary astrocytoma 10.3 PCNA TP53
18 central nervous system hematologic cancer 10.2 BCL6 TP53
19 helicobacter pylori infection 10.2
20 adenocarcinoma 10.2
21 primary effusion lymphoma 10.2 BCL6 VEGFA
22 lipodermatosclerosis 10.2 PCNA VEGFA
23 acinar cell carcinoma 10.2 BCL10 TP53
24 rh isoimmunization 10.2 ALB BCL10
25 lymphoma, hodgkin, classic 10.2
26 ulcerative stomatitis 10.2 ALB TP53
27 severe nonproliferative diabetic retinopathy 10.2 ALB VEGFA
28 gastritis 10.1
29 esophagus adenocarcinoma 10.1 ATP12A TP53
30 capillary disease 10.1 ALB ATP12A
31 acroosteolysis 10.1 ALB VEGFA
32 drug allergy 10.1 ALB ATP12A
33 plasmablastic lymphoma 10.1
34 background diabetic retinopathy 10.1 ALB VEGFA
35 castleman disease 10.1 BCL6 VEGFA
36 inverted papilloma 10.1 PCNA TP53
37 hypertensive nephropathy 10.1 ALB VEGFA
38 polyposis, skin pigmentation, alopecia, and fingernail changes 10.1 ALB ATP12A
39 jejunoileitis 10.1 ALB ATP12A
40 esophageal varix 10.1 ALB ATP12A
41 juvenile nasopharyngeal angiofibroma 10.1 PCNA VEGFA
42 aspiration pneumonia 10.1 ALB ATP12A
43 primary peritoneal carcinoma 10.1 TP53 VEGFA
44 blind loop syndrome 10.1 ALB ATP12A
45 mature b-cell neoplasm 10.1 BCL6 TP53
46 peptic ulcer perforation 10.1 ALB ATP12A
47 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 10.1 BCL2 BCL6
48 fallopian tube carcinoma 10.1 TP53 VEGFA
49 gastric cancer 10.1
50 hydrops, lactic acidosis, and sideroblastic anemia 10.1 ALB VEGFA

Graphical network of the top 20 diseases related to Gastric Lymphoma:



Diseases related to Gastric Lymphoma

Symptoms & Phenotypes for Gastric Lymphoma

GenomeRNAi Phenotypes related to Gastric Lymphoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.62 BAX BCL10 BCL2 PCNA TP53
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.62 BAX BCL10 BCL2 PCNA TP53
3 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.26 BAX BCL2 PCNA TP53

MGI Mouse Phenotypes related to Gastric Lymphoma:

47 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.06 ALB BAX BCL10 BCL2 BCL6 PCNA
2 cellular MP:0005384 10.04 ALB BAX BCL10 BCL2 BCL6 TP53
3 growth/size/body region MP:0005378 9.98 ATP12A BAX BCL2 BCL6 PCNA TP53
4 hematopoietic system MP:0005397 9.95 BAX BCL10 BCL2 BCL6 PCNA TP53
5 mortality/aging MP:0010768 9.92 ALB BAX BCL10 BCL2 BCL6 PCNA
6 immune system MP:0005387 9.91 BAX BCL10 BCL2 BCL6 PCNA TP53
7 digestive/alimentary MP:0005381 9.88 ALB ATP12A BCL2 TP53 VEGFA
8 muscle MP:0005369 9.73 ALB BAX BCL2 BCL6 TP53 VEGFA
9 neoplasm MP:0002006 9.55 ALB BAX BCL2 TP53 VEGFA
10 renal/urinary system MP:0005367 9.43 ALB ATP12A BAX BCL2 TP53 VEGFA
11 reproductive system MP:0005389 9.1 BAX BCL2 BCL6 PCNA TP53 VEGFA

Drugs & Therapeutics for Gastric Lymphoma

Drugs for Gastric Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 105)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 26787-78-0 33613
2
Metronidazole Approved Phase 4,Phase 3,Phase 2 443-48-1 4173
3
Clarithromycin Approved Phase 4,Phase 3,Phase 2,Not Applicable 81103-11-9 84029
4
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
5
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
6
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
7
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2 564-25-0 54671203
8
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
9
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
10
Ofloxacin Approved Phase 4 82419-36-1 4583
11 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Not Applicable
12 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Not Applicable
13 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Not Applicable
14 Antiparasitic Agents Phase 4,Phase 3,Phase 2
15 Antacids Phase 4,Phase 3,Phase 2,Not Applicable
16 Antiprotozoal Agents Phase 4,Phase 3,Phase 2
17 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Not Applicable
18 Proton Pump Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
19 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
20 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
21 Antibiotics, Antitubercular Phase 4,Phase 2,Not Applicable
22 Antimalarials Phase 4,Phase 2
23 Renal Agents Phase 4
24 Pharmaceutical Solutions Phase 4
25 Topoisomerase Inhibitors Phase 4
26 Anti-Infective Agents, Urinary Phase 4
27 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
28
Chlorambucil Approved Phase 3,Phase 2 305-03-3 2708
29
Tinidazole Approved, Investigational Phase 3 19387-91-8 5479
30
Omeprazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 73590-58-6 4594
31
rituximab Approved Phase 3,Phase 2,Phase 1 174722-31-7 10201696
32 Antineoplastic Agents, Alkylating Phase 3,Phase 2
33 Alkylating Agents Phase 3,Phase 2
34 Antineoplastic Agents, Immunological Phase 3,Phase 2,Phase 1
35 Immunologic Factors Phase 3,Phase 2,Phase 1
36 Antirheumatic Agents Phase 3,Phase 2
37
Lenalidomide Approved Phase 2 191732-72-6 216326
38
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
39
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
40
Tetracycline Approved, Vet_approved Phase 2 60-54-8 5353990
41
Bismuth subsalicylate Approved, Vet_approved Phase 2 14882-18-9 53629521
42
Loperamide Approved Phase 2 53179-11-6 3955
43
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
44
Cyclophosphamide Approved, Investigational Phase 2 6055-19-2, 50-18-0 2907
45
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
46
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
47
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
48
Fludarabine Approved Phase 2 75607-67-9, 21679-14-1 30751
49
Vidarabine Approved, Investigational Phase 2 24356-66-9 21704 32326
50
Everolimus Approved Phase 2 159351-69-6 6442177 70789204

Interventional clinical trials:

(show all 45)
# Name Status NCT ID Phase Drugs
1 Intraluminal Metronidazole Powder Monotherapy for Helicobacter Pylori Infection Completed NCT03524833 Phase 4 Metronidazole;Lansoprazole, Amoxicillin, Metronidazole
2 Intraluminal Amoxicillin Powder Monotherapy for Helicobacter Pylori Infection Completed NCT03521726 Phase 4 Amoxicillin;Rabeprazole, Amoxicillin
3 Intraluminal Clarithromycin Powder Monotherapy for Helicobacter Pylori Infection Completed NCT03516669 Phase 4 Clarithromycin;Amoxicillin, Clarithromycin
4 Intraluminal Therapy for Helicobacter Pylori Infection Completed NCT03124420 Phase 4 Lansoprazole;Amoxicillin;Clarithromycin
5 High Dose Dual Therapy (HDDT) for Eradication of Helicobacter Pylori Infection Recruiting NCT02553083 Phase 4 Nexium 40 mg;amoxicillin 1.5 gr;doxycycline 200 mg;Nexium 20 mg;clarythromicin 500 mg;amoxicillin 1gr
6 Intraluminal Mono-antibiotic Therapy for Helicobacter Pylori Infection - A Comparison of Levofloxacin Powder and Levofloxacin Solution Not yet recruiting NCT03832465 Phase 4 Levofloxacin film-coated tablet;Levofloxacin intravenous solution
7 Chlorambucil Compared With No Further Therapy Following Anti-Helicobacter Therapy in Treating Patients With Low-Grade Lymphoma of the Stomach Unknown status NCT00003617 Phase 3 chlorambucil;clarithromycin;omeprazole;tinidazole
8 Helicobacter – Lymphoma – Radiation Part I: Eradication, Part II: Radiation Unknown status NCT00154440 Phase 3 proton pump inhibitor;clarithromycin;amoxicillin;metronidazole
9 Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma Active, not recruiting NCT00210353 Phase 3 chlorambucil (drug);rituximab+chlorambucil;rituximab
10 Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type Unknown status NCT00923663 Phase 2 Lenalidomide
11 Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas Unknown status NCT00783367 Phase 2 lenalidomide-low dose dexamethasone plus rituximab;Lenalidomide + Rituximab
12 Antibiotic Therapy in Treating Patients With Low Grade Gastric Lymphoma Completed NCT00003151 Phase 2 amoxicillin;clarithromycin;metronidazole hydrochloride;omeprazole;tetracycline hydrochloride
13 Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach Completed NCT00002682 Phase 2 Amoxicillin;Bismuth Subsalicylate;Clarithromycin;Metronidazole Hydrochloride;Omeprazole;Tetracycline Hydrochloride
14 Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin`s Lymphoma Completed NCT00204659 Phase 2 Rituximab + CHOP chemotherapy
15 Velcade in MALT Lymphoma Patients Completed NCT00373906 Phase 2 Bortezomib (Velcade)
16 Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients Completed NCT00373646 Phase 2 Thalidomide, Pharmion
17 Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Completed NCT01015248 Phase 2 Rituximab and Bendamustine
18 VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy Completed NCT00210327 Phase 2 Bortezomib (drug)
19 Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma Completed NCT00117156 Phase 2 Fludarabine;Rituximab
20 Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue Completed NCT01611259 Phase 2 Rituximab and Lenalidomide
21 A Clinico-Pathological Study to Investigate the Possible Infective Causes of Non-Hodgkin Lymphoma of the Ocular Adnexae Completed NCT01010295 Phase 2 doxycycline (tetracycline)
22 Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL) Completed NCT01164267 Phase 2 Everolimus
23 Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Completed NCT00656812 Phase 2 Rituximab;2-CdA
24 Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Completed NCT00989586 Phase 1, Phase 2
25 A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma Completed NCT00081809 Phase 2 autologous human tumor-derived HSPPC-96
26 Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone Lymphoma Recruiting NCT03031483 Phase 2 clarithromycin and lenalidomide
27 Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma Active, not recruiting NCT01808599 Phase 2 Chlorambucil;Rituximab i.v.;Rituximab s.c.
28 R-CVP for the Treatment of Non-conjunctival Ocular Adnexal MALT Lymphoma (OAML) Active, not recruiting NCT01427114 Phase 2 rituximab, cyclophosphamide, vincristine, and prednisolone
29 Involved Field Radiotherapy for Non-gastric Marginal Zone Lymphoma Active, not recruiting NCT00377195 Phase 2
30 Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma Not yet recruiting NCT03261349 Phase 2 Ledipasvir and sofosbuvir
31 VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy Terminated NCT00210392 Phase 2 Bortezomib (drug)
32 Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies Recruiting NCT02924402 Phase 1
33 Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. Not yet recruiting NCT03886649 Phase 1 Copanlisib;Venetoclax
34 Immediate Detection of Helicobacter Infection With a New Electrochemical System. Unknown status NCT01234389 Not Applicable
35 The Revolutions of Helicobacter Pylori Infection, Bacterial Density, and Histological Features After Antrectomy Unknown status NCT00441831
36 Reinfection After Eradication of Helicobacter Pylori Infection Unknown status NCT02674802
37 Endomicroscopy and Gastric MALT-lymphoma Completed NCT01583699 Not Applicable
38 Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori Completed NCT01264822 Rabeprazole Sodium
39 Prospective Study of First-line Antibiotic Therapy for Early-stage Gastric MALT Lymphoma for Treatment Outcome Completed NCT00327132 Not Applicable Omeprazole, Amoxicillin, Clarithromycin
40 Eradication of Helicobacter Pylori in the Management of Stage IE & IIE-1 Primary Low-grade B Cell Lymphoma of MALToma Completed NCT00201422 Not Applicable
41 Drug Use Surveillance of Takecab for "Supplement to Helicobacter Pylori Eradication" Completed NCT03219723 Vonoprazan;Amoxicillin hydrate;Clarithromycin;Metronidazole
42 Immunological Repertoire in Patients With Lymphoma and Chronic Lymphocytic Leukemia Completed NCT02520895
43 Prospective Study of Frontline H Pylori Eradication in the Treatment of Early-stage Extragastric MALT Lymphoma Recruiting NCT02987127
44 Low-Dose Radiation Therapy in Treating Patients With Stage I-IV Stomach MALT Lymphoma Recruiting NCT03680586 Not Applicable
45 Tumor Registry of Lymphatic Neoplasia Active, not recruiting NCT00889798

Search NIH Clinical Center for Gastric Lymphoma

Cochrane evidence based reviews: familial primary gastric lymphoma

Genetic Tests for Gastric Lymphoma

Genetic tests related to Gastric Lymphoma:

# Genetic test Affiliating Genes
1 Gastric Lymphoma 30

Anatomical Context for Gastric Lymphoma

MalaCards organs/tissues related to Gastric Lymphoma:

42
B Cells, T Cells, Liver, Kidney, Pancreas, Bone, Bone Marrow

Publications for Gastric Lymphoma

Articles related to Gastric Lymphoma:

(show top 50) (show all 441)
# Title Authors Year
1
Gastric inflammatory fibroid polyp tumor with acute intestinal obstruction-Vanek's tumor can mimick a giant gastrointestinal stromal tumor or a gastric lymphoma. ( 29682464 )
2018
2
Four-dimensional cone-beam computed tomography-guided radiotherapy for gastric lymphoma. ( 29086348 )
2018
3
Primary Gastric Lymphoma: Clinicopathological Profile. ( 29963454 )
2018
4
Primary Gastric Lymphoma, Epidemiology, Clinical Diagnosis, and Treatment. ( 29779412 )
2018
5
Diagnosis of Superficial Gastric Lesions Together with Six Gastric Lymphoma Cases via Probe-Based Confocal Laser Endomicroscopy: A Retrospective Observational Study. ( 30008745 )
2018
6
Epstein-Barr virus-positive mucocutaneous ulcer colliding with extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (malt lymphoma) that developed in the palatine tonsils of an immunocompetent patient after gastric lymphoma relapse. ( 30588472 )
2018
7
Severe upper gastrointestinal bleeding determined by a gastric lymphoma associated with Helicobacter pylori-positive atrophic gastritis. ( 28730251 )
2017
8
Gastric Kaposi's sarcoma simulating gastric lymphoma during endoscopic ultrasound examination. ( 28685740 )
2017
9
Isolated Pulmonary Valve Vegetations in a Patient with Gastric Lymphoma Diagnosed by Endoscopic Ultrasound. ( 29560679 )
2017
10
Gastric lymphoma: association with Helicobacter pylori outer membrane protein Q (HopQ) and cytotoxic-pathogenicity activity island (CPAI) genes. ( 29143724 )
2017
11
The Role of Endoscopic Ultrasound in the Diagnosis and Management of Primary Gastric Lymphoma. ( 28400819 )
2017
12
CT-based radiomics signature for differentiating Borrmann type IV gastric cancer from primary gastric lymphoma. ( 28629560 )
2017
13
Multimodality Treatment of Gastric Lymphoma. ( 28325194 )
2017
14
Clinical manifestations and endoscopic presentations of gastric lymphoma: a multicenter seven year retrospective survey. ( 28617031 )
2017
15
Diffuse large B cell gastric lymphoma a rare disease: the effort to obtain scientific data in a multicenter, multinational retrospective trial. ( 27521853 )
2016
16
Prognostic value of SUVmax measured by pretreatment 18F-FDG PET/CT in patients with primary gastric lymphoma. ( 27482643 )
2016
17
The clinical characteristics of primary gastric lymphoma detected during screening for gastric cancer in Korea. ( 26850225 )
2016
18
18F-FDG PET/CT Imaging of Primary Gastric Lymphoma. ( 27493260 )
2016
19
(18)F-fluorodeoxyglucose positron emission tomography/computed tomography comparison of gastric lymphoma and gastric carcinoma. ( 27678362 )
2016
20
4D-Listmode-PET-CT and 4D-CT for optimizing PTV margins in gastric lymphoma : Determination of intra- and interfractional gastric motion. ( 26902523 )
2016
21
H. pylori-associated gastric lymphoma: Complete remission in an HIV-positive patient treated with HAART and H. pylori eradication therapy. ( 27206927 )
2016
22
Clinical characteristics and prognostic factors of primary gastric lymphoma: A retrospective study with 165 cases. ( 27495029 )
2016
23
Indication for liver transplantation in a patient with a history of a gastric lymphoma. ( 26937630 )
2016
24
High expression of PTPN21 in B-cell non-Hodgkin's gastric lymphoma, a positive mediator of STAT5 activity. ( 26771814 )
2016
25
Massive gastrointestinal bleeding after chemotherapy for gastric lymphoma. ( 26921535 )
2016
26
Survival of patients with gastric lymphoma in Germany and in the United States. ( 25967274 )
2015
27
Colonic inflammation in a samoan immigrant with gastric lymphoma shown by positron emission tomography. ( 25948555 )
2015
28
Primary gastric lymphoma in a soldier presenting as acute gastrointestinal bleeding. ( 28265419 )
2015
29
Refractory peptic ulceration following radiation therapy in primary gastric lymphoma: A report of two cases. ( 25435934 )
2015
30
Spontaneous regression of high grade primary gastric Lymphoma in an untreated viral hepatitis infection. ( 24512317 )
2014
31
Gastrocolic fistula secondary to primary gastric lymphoma. ( 24932326 )
2014
32
A retrospective study of feline gastric lymphoma in 16 chemotherapy-treated cats. ( 24216491 )
2014
33
Radiotherapy for gastric lymphoma: a planning study of 3D conformal radiotherapy, the half-beam method, and intensity-modulated radiotherapy. ( 25161174 )
2014
34
Treatment modalities in primary gastric lymphoma: the effect of rituximab and surgical treatment. A study by the Anatolian Society of Medical Oncology. ( 25258586 )
2014
35
(18)F-fluorodeoxyglucose positron emission tomography/computed tomography findings of gastric lymphoma: Comparisons with gastric cancer. ( 25202405 )
2014
36
Clinicopathological characteristics and therapeutic outcomes of synchronous gastric adenocarcinoma and gastric lymphoma. ( 25202092 )
2014
37
The evolving role of surgery for gastric lymphoma: from curative resection to surgical management of complications. ( 25347493 )
2014
38
Malignant gastric lymphoma with spontaneous perforation. ( 23329705 )
2013
39
Hepatic dysfunction after radiotherapy for primary gastric lymphoma. ( 23283868 )
2013
40
Primary Gastric Lymphoma Presenting as Acute Pancreatitis: A Case Report. ( 23846949 )
2013
41
Clonal immunoglobulin heavy chain and T-cell receptor I^ gene rearrangements in primary gastric lymphoma. ( 24039368 )
2013
42
Primary submucosal nodular plasmacytoma of the stomach: a poorly recognized variant of gastric lymphoma. ( 23425357 )
2013
43
Primary gastric lymphoma: utility of 18F-fluorodeoxyglucose positron emission tomography-computed tomography for detecting relapse after treatment. ( 23043310 )
2013
44
Predictive value of endoscopic ultrasound in diagnosis and staging of primary gastric lymphoma. ( 23837259 )
2013
45
Unconvincing diagnosis of a rare subtype of primary gastric lymphoma with incongruent endoscopic presentation: a case of gastric schwannoma. ( 24365735 )
2013
46
Review of the molecular profile and modern prognostic markers for gastric lymphoma: how do they affect clinical practice? ( 22564515 )
2012
47
Primary gastric lymphoma: conservative treatment modality is not inferior to surgery for early-stage disease. ( 22988526 )
2012
48
Correlational study of vascular endothelial growth factor expression and microvessel density in primary malignant gastric lymphoma. ( 21710234 )
2012
49
A case of eosinophilic gastroenteritis mimicking gastric lymphoma associated with pancreatitis due to duodenal involvement. ( 23161306 )
2012
50
The diagnostic characteristics of a group of patients with primary gastric lymphoma: macroscopic, histopathological and immunohistochemical aspects. ( 22732804 )
2012

Variations for Gastric Lymphoma

Expression for Gastric Lymphoma

Search GEO for disease gene expression data for Gastric Lymphoma.

Pathways for Gastric Lymphoma

Pathways related to Gastric Lymphoma according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.82 BAX BCL2 TP53 VEGFA
2
Show member pathways
12.8 BAX BCL6 PCNA TP53
3
Show member pathways
12.79 BAX BCL2 TP53 VEGFA
4
Show member pathways
12.69 BAX BCL2 PCNA TP53 VEGFA
5 12.65 BAX BCL2 TP53 VEGFA
6
Show member pathways
12.58 BAX BCL2 PCNA TP53 VEGFA
7
Show member pathways
12.51 BAX BCL2 PCNA TP53
8
Show member pathways
12.5 BAX BCL2 TP53 VEGFA
9
Show member pathways
12.3 BAX BCL2 TP53
10
Show member pathways
12.25 BAX PCNA TP53
11
Show member pathways
12.24 BAX BCL2 TP53
12 12.21 BAX PCNA TP53
13 12.11 BAX BCL6 TP53
14 12.1 BAX BCL10 BCL2
15
Show member pathways
12.09 BAX BCL2 TP53
16 12.08 BAX BCL10 BCL2
17
Show member pathways
12.06 BAX BCL2 TP53
18 12.02 BAX TP53 VEGFA
19 11.99 BAX BCL2 TP53
20 11.93 BCL2 TP53 VEGFA
21 11.9 BCL2 TP53 VEGFA
22
Show member pathways
11.86 BAX BCL2 TP53
23 11.84 BAX BCL2 TP53
24
Show member pathways
11.81 BAX BCL2 TP53
25 11.81 BAX BCL2 TP53 VEGFA
26 11.77 BCL2 PCNA TP53
27
Show member pathways
11.76 BAX BCL6 TP53
28
Show member pathways
11.72 BAX PCNA TP53
29 11.7 BAX BCL2 VEGFA
30 11.65 BAX BCL2 TP53
31 11.54 BCL2 TP53 VEGFA
32 11.52 BAX BCL2 TP53
33 11.52 BAX BCL2 BCL6 TP53
34 11.44 BCL10 PCNA TP53
35 11.35 BAX BCL2
36 11.35 PCNA TP53
37 11.34 BAX BCL2 TP53
38 11.31 BCL2 BCL6 TP53 VEGFA
39 11.29 BAX TP53
40 11.24 BAX BCL2 TP53
41 11.19 BAX BCL2
42 11.19 PCNA TP53
43 11.14 PCNA TP53
44 11.14 BAX BCL2 BCL6 PCNA TP53
45 11.12 BAX BCL2
46 11.11 BAX TP53 VEGFA
47 11.02 BAX BCL2
49 10.9 BAX BCL2
50
Show member pathways
10.78 BAX BCL2 TP53

GO Terms for Gastric Lymphoma

Cellular components related to Gastric Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 9.46 ALB BCL10 BCL2 TP53
2 replication fork GO:0005657 8.96 BCL6 PCNA
3 pore complex GO:0046930 8.62 BAX BCL2

Biological processes related to Gastric Lymphoma according to GeneCards Suite gene sharing:

(show all 46)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.99 BAX BCL10 BCL2 TP53
2 negative regulation of cell proliferation GO:0008285 9.91 BAX BCL2 BCL6 TP53
3 cell proliferation GO:0008283 9.88 BAX BCL2 PCNA TP53
4 positive regulation of apoptotic process GO:0043065 9.85 BAX BCL10 BCL6 TP53
5 negative regulation of apoptotic process GO:0043066 9.85 ALB BCL2 BCL6 TP53 VEGFA
6 cytokine-mediated signaling pathway GO:0019221 9.81 BCL2 BCL6 TP53 VEGFA
7 cellular response to hypoxia GO:0071456 9.78 BCL2 TP53 VEGFA
8 negative regulation of cell growth GO:0030308 9.77 BCL2 BCL6 TP53
9 kidney development GO:0001822 9.77 BAX BCL2 VEGFA
10 cellular response to DNA damage stimulus GO:0006974 9.77 BAX BCL2 BCL6 PCNA TP53
11 cellular response to glucose starvation GO:0042149 9.7 BCL2 TP53
12 cellular response to organic substance GO:0071310 9.7 BAX BCL2
13 positive regulation of B cell proliferation GO:0030890 9.69 BCL2 BCL6
14 neuron apoptotic process GO:0051402 9.69 BAX BCL2
15 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.68 BAX BCL2
16 extrinsic apoptotic signaling pathway via death domain receptors GO:0008625 9.68 BAX BCL2
17 intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress GO:0070059 9.68 BAX BCL2
18 negative regulation of fibroblast proliferation GO:0048147 9.68 BAX TP53
19 homeostasis of number of cells within a tissue GO:0048873 9.67 BAX BCL2
20 intrinsic apoptotic signaling pathway GO:0097193 9.67 BAX TP53
21 cell aging GO:0007569 9.67 BCL2 TP53
22 positive regulation of release of cytochrome c from mitochondria GO:0090200 9.66 BAX TP53
23 regulation of mitochondrial membrane potential GO:0051881 9.66 BAX BCL2
24 intrinsic apoptotic signaling pathway by p53 class mediator GO:0072332 9.65 BAX TP53
25 negative regulation of apoptotic signaling pathway GO:2001234 9.65 BAX BCL2
26 positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway GO:1900740 9.65 BCL2 TP53
27 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.65 BAX PCNA TP53
28 B cell homeostasis GO:0001782 9.64 BAX BCL2
29 apoptotic mitochondrial changes GO:0008637 9.64 BAX BCL2
30 release of cytochrome c from mitochondria GO:0001836 9.63 BAX BCL2
31 positive regulation of protein oligomerization GO:0032461 9.63 BAX TP53
32 endoplasmic reticulum calcium ion homeostasis GO:0032469 9.62 BAX BCL2
33 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.62 ATP12A BAX
34 cellular response to UV GO:0034644 9.61 BAX PCNA TP53
35 regulation of mitochondrial membrane permeability GO:0046902 9.58 BCL2 TP53
36 ovarian follicle development GO:0001541 9.58 BAX BCL2 VEGFA
37 positive regulation of cellular component movement GO:0051272 9.57 BCL6 VEGFA
38 regulation of protein heterodimerization activity GO:0043497 9.56 BAX BCL2
39 B cell apoptotic process GO:0001783 9.54 BAX BCL10
40 regulation of protein homodimerization activity GO:0043496 9.52 BAX BCL2
41 leukocyte homeostasis GO:0001776 9.49 BAX BCL2
42 positive regulation of intrinsic apoptotic signaling pathway GO:2001244 9.33 BAX BCL2 TP53
43 positive regulation of developmental pigmentation GO:0048087 9.32 BAX BCL2
44 regulation of nitrogen utilization GO:0006808 9.26 BAX BCL2
45 response to gamma radiation GO:0010332 9.13 BAX BCL2 TP53
46 regulation of apoptotic process GO:0042981 9.02 BAX BCL10 BCL2 BCL6 TP53

Molecular functions related to Gastric Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.62 BAX BCL2 TP53 VEGFA
2 channel activity GO:0015267 9.43 BAX BCL2
3 chaperone binding GO:0051087 9.43 ALB BAX TP53
4 histone acetyltransferase binding GO:0035035 9.4 PCNA TP53
5 protein phosphatase 2A binding GO:0051721 9.37 BCL2 TP53
6 protease binding GO:0002020 9.33 BCL10 BCL2 TP53
7 identical protein binding GO:0042802 9.23 ALB BAX BCL10 BCL2 BCL6 PCNA
8 BH3 domain binding GO:0051434 8.96 BAX BCL2

Sources for Gastric Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....